528 related articles for article (PubMed ID: 27133752)
1. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
[TBL] [Abstract][Full Text] [Related]
2. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
[TBL] [Abstract][Full Text] [Related]
3. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
[TBL] [Abstract][Full Text] [Related]
4. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.
Nishiyama N; Honda T; Sema M; Kawahara T; Jin Y; Natsume I; Chiaki T; Yamashita T; Tsukada Y; Taki R; Miyashita Y; Saito K; Tateishi T; Sakashita H; Miyazaki Y
Int J Clin Oncol; 2020 Feb; 25(2):282-291. PubMed ID: 31720993
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
Nakao S; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Anticancer Res; 2019 Oct; 39(10):5725-5731. PubMed ID: 31570474
[TBL] [Abstract][Full Text] [Related]
7. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
[TBL] [Abstract][Full Text] [Related]
8. Glasgow Prognostic Score predicts chemotherapy-triggered acute exacerbation-interstitial lung disease in patients with non-small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Mar; 12(5):667-675. PubMed ID: 33480111
[TBL] [Abstract][Full Text] [Related]
9. Is operation safe for lung cancer patients with interstitial lung disease on computed tomography?
Tang H; Ren Y; She Y; Dai C; Wang T; Su H; Sun W; Jiang G; Chen C
Ther Adv Respir Dis; 2020; 14():1753466620971137. PubMed ID: 33167797
[TBL] [Abstract][Full Text] [Related]
10. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Takahashi T
Lung Cancer; 2018 Jul; 121():48-53. PubMed ID: 29858026
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
Okuda K; Hirose T; Oki Y; Murata Y; Kusumoto S; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Ohnishi T; Ohmori T
Anticancer Res; 2012 Dec; 32(12):5475-80. PubMed ID: 23225454
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of
Akaike K; Saruwatari K; Oda S; Shiraishi S; Takahashi H; Hamada S; Iyama S; Horio Y; Tomita Y; Saeki S; Okamoto S; Ichiyasu H; Fujii K; Sakagami T
Int J Clin Oncol; 2020 Apr; 25(4):681-690. PubMed ID: 31781994
[TBL] [Abstract][Full Text] [Related]
13. Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.
Ozawa Y; Akahori D; Koda K; Abe T; Hasegawa H; Matsui T; Tanahashi M; Niwa H; Yamada K; Yokomura K; Suda T
Cancer Chemother Pharmacol; 2016 May; 77(5):1031-8. PubMed ID: 27048413
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.
Kelly CA; Saravanan V; Nisar M; Arthanari S; Woodhead FA; Price-Forbes AN; Dawson J; Sathi N; Ahmad Y; Koduri G; Young A;
Rheumatology (Oxford); 2014 Sep; 53(9):1676-82. PubMed ID: 24758887
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N
Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
18. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Niho S; Goto K; Yoh K; Kim YH; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Jpn J Clin Oncol; 2006 May; 36(5):269-73. PubMed ID: 16702163
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis.
Kono M; Fujita Y; Takeda K; Miyashita K; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Enomoto N; Nakamura Y; Suda T; Nakamura H
Respir Med; 2019; 154():122-126. PubMed ID: 31238182
[TBL] [Abstract][Full Text] [Related]
20. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
